Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems

Chiara Lestuzzi; Lucia Tartuferi; Elda Viel; Angela Buonadonna; Emanuela Vaccher; Massimiliano Berretta

doi:10.1634/theoncologist.2020-0053

Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems

Oncologist. 2020 Aug;25(8):e1254. doi: 10.1634/theoncologist.2020-0053. Epub 2020 Jun 17.

Authors

Chiara Lestuzzi¹, Lucia Tartuferi¹, Elda Viel¹, Angela Buonadonna², Emanuela Vaccher², Massimiliano Berretta²

Affiliations

¹ Cardiology Department, AAS5 Friuli Occidentale; and Cardiology and Cardio-Oncology Rehabilitation Unit, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy.
² Oncology Department, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, IRCCS, Aviano, Italy.

Abstract

This letter to the editor focuses on a recent report of a retrospective case‐control study of fluoropyrimidine‐associated cardiotoxicity in cancer patients.

Publication types

Letter
Comment

MeSH terms

Capecitabine
Case-Control Studies
Fluorouracil*
Humans
Retrospective Studies

Substances

Capecitabine
Fluorouracil